IRIDEX (NASDAQ:IRIX) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a report released on Sunday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

NASDAQ:IRIX opened at $1.26 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. The company has a 50-day moving average of $1.58 and a 200-day moving average of $1.69. IRIDEX has a 52 week low of $1.22 and a 52 week high of $3.65. The company has a market capitalization of $20.96 million, a price-to-earnings ratio of -1.88 and a beta of 0.94.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.